1093 Overview

Collaboration Announcement: Innovent Biologics is partnering with Takeda Pharmaceutical to develop cancer therapies, with potential earnings of up to $11.4 billion for the Chinese company.

Trend in Pharma Collaborations: This partnership reflects a growing trend of collaborations between Chinese pharmaceutical firms and international companies aiming to enhance their global presence and leverage China's drug development capabilities.

Impact on Asian Markets: Pharmaceutical stocks in Asian markets declined following President Trump's announcement of new tariffs, particularly a 100% tariff on drugs from companies not building manufacturing plants in the U.S.

Tariff Implementation Date: The new tariff will take effect on October 1st, 2025, as stated by Trump on his social media platform, Truth Social, although specific details were not provided.

Market Reaction: Copper futures declined in Asia and stock markets showed mixed results as investors reacted to President Trump's new tariff threats.

Tariff Developments: The U.S. has informed 14 countries about reciprocal tariffs, bringing sector-specific duties back into focus.

Strategic Collaboration: AstraZeneca has partnered with China's CSPC Pharmaceuticals in a research collaboration focused on AI-driven drug discovery, valued at up to $5.33 billion.

Research Goals: The partnership aims to develop novel oral candidates for treating various diseases across multiple indications.

CSPC Pharmaceutical Licensing Agreement: CSPC Pharmaceutical is poised to benefit from a licensing agreement with AstraZeneca for a pre-clinical lipid-lowering drug, which includes an upfront payment of US$100 million.

Analyst Outlook: Nomura's analyst Jialin Zhang expresses optimism about the deal's impact on CSPC, maintaining a buy rating and a target price of HK$9.29, while shares currently trade at HK$7.04.